Home
OverviewAbout10 LeapsCollaborationImpact
OverviewLeaps TalksChapter FilmsLeaps.orgPartners
AgricultureHealth
OverviewAnnual ReviewBreakthrough StudyPress ReleasesIn the NewsReportsLeaps LeadershipPress KitMedia Contact
Team
  • Approach
    • Overview
    • About
    • 10 Leaps
    • Collaboration
    • Impact
  • Engagement
    • Overview
    • Leaps Talks
    • Chapter Films
    • Leaps.org
    • Partners
    • Agriculture
    • Health
  • News
    • Overview
    • Annual Review
    • Breakthrough Study
    • Press Releases
    • In the News
    • Reports
    • Leaps Leadership
    • Press Kit
    • Media Contact
  • Team
ContactImprintPrivacy StatementConditions of Use
sign up for our newsletter
see more companies

Recode Therapeutics

recode therapeutics health logo

Vision

To power the next wave of genetic medicines through superior delivery.

Approach

ReCode is revolutionizing the way genetic medicines are delivered with its next generation Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform. ReCode’s SORT LNP platform is the foundation for its pipeline of disease-modifying mRNA and gene correction therapeutics and is poised to unlock the promise of precision genetic medicines with the ability to selectively target organs and cells beyond the liver.

Recode Therapeutics is addressing

  • Leap 01 / Cure genetic diseases

CEO:

Shehnaaz Suliman, M.D., MBA, M.Phil.

Founders:

Arthur Johnson, Ph.D., Philip Thomas, Ph.D, Daniel Siegwart, Ph.D., and Michael Torres, Ph.D. founded the original ReCode. David Lockhart, Ph.D, Leon Chen, Ph.D and Peter Thompson, M.D. founded TranscripTx, which merged with ReCode in 2020 to create the ReCode that exists today.

First investment:

June 2022

www.recodetx.com